Wang, Yinxi
Sun, Wenwen
Karlsson, Emelie
Kang Lövgren, Sandy
Ács, Balázs
Rantalainen, Mattias
Robertson, Stephanie
Hartman, Johan
Funding for this research was provided by:
Karolinska Institute
Article History
Received: 28 January 2024
Accepted: 26 February 2024
First Online: 9 April 2024
Declarations
:
: The study was performed in line with the principles of the Declaration of Helsinki. The study was approved by the Swedish Ethical Review Authority (2019 − 01908 with amendment 2021-00017, 2022-01102-02).
: No additional informed consent was required in accordance with ethical approval in this non-interventional collection and analysis of data from patient records.
: The authors declare the following financial interest/personal relationships that may be considered as potential competing interests: Y.W. is employee at Stratipath AB and holds employee stock options. W.S. has nothing to declare. E.K. is employee at Stratipath AB. S.K.L. is employee at Stratipath AB and holds employee stock options. B.A. is an editorial board member of Breast Cancer Research and Treatment. M.R. has obtained speaker’s honoraria from Pfizer and is co-founder and shareholder of Stratipath AB. S.R. is employee at Stratipath AB and holds employee stock options. J.H. has obtained speaker’s honoraria or advisory board renumerations from Roche, Novartis, AstraZeneca, Pfizer, Eli Lily, MSD and Gilead, and has received institutional research support from Cepheid, Novartis, Roche and AstraZeneca. J.H. is co-founder and shareholder of Stratipath AB.